Skip to main content

Overview

Dr. Lee completed his undergraduate degree at Duke University (Durham, NC), and then moved to the University of Pennsylvania (Philadelphia, PA) to complete both his MD and his MBA. He then moved to New York and began working at Weill Cornell Medical College/New York-Presbyterian Hospital, specifically within the Department of Urology, while completing both his residency rotation and a fellowship.

Dr. Lee was appointed to a full-time faculty position within the Department of Urology in July 2011 after completing his fellowship. He currently practices within the Iris Cantor Men's Health Center, which is located at 425 E 61st St, 12th floor.

While completing his residency at Weill Cornell Medical College, Dr. Lee was awarded the Society for Male Reproduction and Urology (SMRU) Traveling Scholar Award (2006), the Society for the Study of Male Reproduction (SSMR) Men’s Health Traveling Fellowship (2007), the Empire Clinical Research Investigator Program Grant (2007), the New York Weill Cornell Medical Center Alumni Council Distinguished Housestaff Award (2008), and the Doctors of the World Health and Human Rights Leadership Award (2008).

Dr. Lee is an active participant in translational research and is currently involved in several protocols as either primary or co-investigator that includes NIH, non-profit foundation, and industry support. He takes part in the peer review process of other’s research as a journal reviewer for European Urology, Journal of Urology, British Journal of Urology International, and Advances in Urology.

His current research interests include BPH, male and female pelvic health, female urology, incontinence, pelvic organ prolapse, health outcomes, cost effectiveness analysis, pelvic reconstruction, bioengineering, and nanoparticle therapy.

Dr. Lee's office is located within the Iris Cantor Men's Health Center at 425 E. 61st Street. You may contact the office with questions or to make an appointment at 646-962-4811.

Highlights

  1. 1
    The Lancet. Global health · 2022
    PMID: 36113534PMCID: PMC9638032DOISenior author14 citations
  2. 2
    PloS one · 2020
    PMID: 32442198PMCID: PMC7244118DOISenior author1 citations
  3. 3
    Advances in experimental medicine and biology · 2021
    PMID: 34453742DOISenior author14 citations

Publications

193 publications

Active

4 grants
  • MPI
    A Training Infrastructure to Support Voluntary Male Circumcision in sub-Saharan Africa
    Bill & Melinda Gates Foundation · 2019–2027
    INV-003436
  • MPI
    Outcomes of Metastatic Urothelial Cancer Patients Selected for Surgery after Immunotherapy
    American Urological Association · 2024–2027
    UCF 234486-01
  • PI
    Improving Urology Standardized Letter of Recommendation and Development of an Electronic Version
    Society of Academic Urologists · 2023–2026
    SAU 231848-01
  • PI
    Investigating the role of leptin in clear cell renal cell carcinoma and the obesity paradox
    Urology Care Foundation · 2023–2026
    UCF 228060-01
Completed grants (2)
  • PI
    Evaluation of the ShangRing vs. Mogen Clamp for Early Infant Male Circumcision in Sub-Saharan Africa
    Bill & Melinda Gates Foundation · 2016–2023
    OPP1158451
  • KP
    Acceptability and Safety of Shang Ring Circumcision
    National Institute of Allergy and Infectious Diseases · 2010–2012 · via The Johns Hopkins University
    U01AI075115-05EWO

Clinical research

2 studies

Active

1 study
  • PI
    The MSKCC Bladder Oncogenome Living Biobank Project: Prospective Creation of Patient Derived Xenograft Models and Organoids
    Memorial Sloan Kettering Cancer Center · OPEN TO ACCRUAL (as of 2025)
Completed & closed trials (1)
  • PI
    A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
    NA · Urotronic, Inc. · IRB STUDY CLOSURE (as of 2025)
    Benign Prostatic Hyperplasia
    NCT04131907

News mentions

  • ShangRing Circumcision Device Could Boost HIV Prevention Efforts
    September 13, 2022

    An easy-to-use device for infant circumcision has proved to be safe in an international randomized controlled clinical trial led by Weill Cornell Medicine physician-scientists. The results suggest that the device could boost efforts to increase circumcision rates and prevent HIV in low-resource settings where early infant circumcision is not widespread.

External relationships

Ownership

Johnson & Johnson · Merck & Co., Inc. · Pfizer, Inc.

Speaker/Lecturer

American Urological Association